Brief: Hansa Biopharma Q3 Operating Loss Widens To SEK 148.2 Million
21/10/2021 07:09
Oct 21 (Reuters) - Hansa Biopharma AB HNSA.ST :
* Q3 NET REVENUE SEK 4.9 MILLION VERSUS SEK 0.8 MILLION YEAR
AGO
* Q3 OPERATING LOSS SEK 148.2 MILLION VERSUS LOSS SEK 123.4
MILLION YEAR AGO
Source text for Eikon: ID:nWkr2MbfM7
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS